重组人干扰素与利巴韦林治疗小儿重症手足口病的临床疗效对比评价

Comparative Evaluation of Clinical Efficacy of Recombinant Human Interferon and Ribavirin in the Treatment of Severe Hand, Foot and Mouth Disease in Children

目的探讨小儿重症手足口病治疗中应用重组人干扰素与利巴韦林治疗的临床价值及疗效改善效果。方法遴选2018年1月—2020年12月泗洪县第一人民医院收治的50例小儿重症手足口病患者。根据治疗模式不同分为两组,对照组25例应用利巴韦林治疗,研究组25例应用重组人干扰素治疗。对比两组临床总疗效、临床症状改善时间、炎症因子水平、不良反应发生率。结果研究组临床总有效率(96.00%)较对照组(68.00%)高,差异有统计学意义(χ^(2)=4.878,P=0.027);研究组临床症状改善时间以及住院时间较对照组均更短,差异有统计学意义(t=3.880、2.165、2.948、4.879、12.753,P<0.05);治疗前,两组炎症因子水平比较,差异无统计学意义(t=0.062、0.099、0.575、0.497,P>0.05),治疗后,研究组炎症因子指标(CRP、TNF-α、IL-6、IL-10)低于对照组,差异有统计学意义(t=5.676、4.292、8.714、15.673,P<0.05);两组不良反应发生率(24.00%vs 12.00%)对比,差异无统计学意义(χ^(2)=0.542,P=0.461)。结论应用重组人干扰素可显著提高小儿重症手足口病临床总疗效,相较利巴韦林治疗更具优势,有利于患儿症状改善,减轻炎症反应,且用药安全性有保障。

Objective To investigate the clinical value and improvement effect of recombinant human interferon and ribavirin in the treatment of severe hand,foot and mouth disease in children.Methods A total of 50 children with severe hand-foot-mouth disease admitted to the First People's Hospital of Sihong County from January 2018 to December 2020 were selected.According to the different treatment modes,25 patients in the control group were treated with ribavirin,and 25 patients in the study group were treated with recombinant human interferon.The total clinical efficacy,clinical symptom improvement time,inflammatory factor levels,and the incidence of adverse reactions were compared between the two groups.Results The total clinical effective rate(96.00%)of the study group was higher than that of the control group(68.00%),and the difference was statistically significant(χ^(2)=4.878,P=0.027).The improvement time of clinical symptoms and hospitalization time in the study group were shorter than those of the control group,and the difference was statistically significant(t=3.880,2.165,2.948,4.879,12.753,P<0.05).There was no statistically significant difference in the levels of inflammatory factors between the two groups before treatment(t=0.062,0.099,0.575,0.497,P>0.05);after treatment,the inflammatory factor indexes(CRP,TNF-α,IL-6,IL-10)in the study group were lower than those in the control group,and the difference was statistically significant(t=5.676,4.292,8.714,15.673,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between groups(24.00%vs 12.00%)(χ^(2)=0.542,P=0.461).Conclusion The application of recombinant human interferon can significantly improve the total clinical efficacy of children with severe hand-foot-mouth disease,which is more advantageous than ribavirin treatment,which is beneficial to the improvement of children's symptoms and the reduction of inflammatory reactions,and the drug safety is guaranteed.